BTK and B-cell chronic lymphocytic leukemia: NX-2127 from Nurix Therapeutics (Table 1) is a potent BTK degrader that is currently in Phase 1 clinical trials, where it has demonstrated over 80% BTK degradation and positive clinical responses in 79% of evaluated CLL patients, irrespective of mutant BTK genotypes, showing promise for overcoming BTK resistance mutations [102].